A randomized controlled trial evaluating the protective effect of a gonadotrophin-releasing hormone agonist on ovarian function in young women with Non-Hodgkin's Lymphoma receiving a 14 day regimen of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP-14).

Trial Profile

A randomized controlled trial evaluating the protective effect of a gonadotrophin-releasing hormone agonist on ovarian function in young women with Non-Hodgkin's Lymphoma receiving a 14 day regimen of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP-14).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Goserelin (Primary) ; Calcium; Norethisterone
  • Indications Female infertility
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 May 2012 Status changed from not yet recruiting to discontinued as reported by Australian New Zealand Clinical Trials Registry record.
    • 05 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top